A part of Watch Media

MedWatchThursday5 October 2023

  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
MedWatchThursday5 October 2023
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
Photo: Staff/Reuters/Ritzau Scanpix

Novo Nordisk suffers Wegovy defeat to Viatris in patent court

It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.
  • Novo Nordisk's semaglutide to be studied for positive effect on alcoholics
  • FDA approves Novo Nordisk drug to treat rare condition


Photo: Novo Nordisk / Pr

Pharmaceutical industry to grow 4% annually towards 2030

For subscribers



Photo: Stine Bidstrup

Zealand Pharma CEO: "We've never been stronger"

For subscribers


Photo: Mike Blake

Eli Lilly's head of diabetes and obesity retires

For subscribers


DNB expects ALK's tablet sales to recover in 2024

For subscribers


Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Photo: Pr

Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

For subscribers


  • Photo: Tom Little

    Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom

    The market’s attention is more focused on public health insurance Medicare’s new price negotiations under the so-called Inflation Reduction Act.

    For subscribers


  • Foto: Alexander Heinl/AP/Ritzau Scanpix

    Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

    Previous studies have shown that alcohol cravings disappeared when people were treated with GLP-1 agonist exanatide.

    For subscribers


  • Photo: Andrew Kelly/Reuters/Ritzau Scanpix

    Low share price may knock Galecto off the stock exchange

    Nasdaq has requested that the biotech company raise its share price to above USD 1.

    For subscribers


  • Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Photo: Liselotte Plenov / Fotorummet / Pr

    Fujifilm expands management with former Leo executive

    The contract manufacturer has hired a chief people officer with immediate effect.

    For subscribers


  • Photo: Mike Segar/Reuters/Ritzau Scanpix

    Snack maker keeps an eye on Novo Nordisk's obesity drug

    ”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.

  • Photo: Tom Little

    FDA approves Novo Nordisk drug to treat rare condition

    The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

    For subscribers


  • Photo: Mike Segar

    FDA rejects atopic dermatitis drug lebrikizumab

    Eli Lilly had expected a launch this year.

    For subscribers


  • Genmab CEO Jan van de Winkel and director general of The Confederation of Danish Industry, Lars Sandahl Sørensen. | Foto: Genmab / PR

    Genmab has officially opened its new headquarters

    The CEO describes the new premises as a symbol of the company’s commitment to advancing science and innovation.

    For subscribers


  • Hans Schambye, adm. direktør i Galecto Biotech | Foto: Henriette Dan Bonde / Pr

    Galecto to lay off 70% of its workforce - announces plans to explore "strategic alternatives"

    ”Biotech is great when things are going well and hard when things are going badly,” says the company’s CEO, Hans Schambye. 

    For subscribers


  • There is a need to safeguard the European patent rules, which are currently being reformed in the EU. The protection of data "plays a central role in the development of new products", says Morten Bødskov, Minister for Industry, Business and Financial Affairs, to MedWatch. (ARCHIVE) | Foto: Thomas Borberg

    Minister: Several countries are against key proposal in controversial EU reform

    Several countries will oppose a change in data protection in the EU, Denmark’s Minister for Industry, Business and Financial Affairs tells MedWatch.

    For subscribers


  • The FDA has updated the package label of Novo Nordisk's diabetes drug, Ozempic, with a warning about intestinal blockage disorder as a possible side effect. | Foto: Tom Little/Reuters/Ritzau Scanpix

    FDA updates Novo Nordisk's Ozempic drug label with side effect alert

    The diabetes drug might cause a potentially fatal intestinal blockage, the authorities warn.

    For subscribers


  • Foto: Andrew Kelly

    FDA to support new orphan drugs through pilot program

    Companies developing drugs for rare diseases can apply to be part of a new FDA pilot program, starting at the beginning of the year.

    For subscribers


  • Vaccine breakthrough behind mRNA shots wins Nobel Prize

    The two scientists will share the 11 million-krona ( USD 1 million) award, the Nobel Assembly at the Karolinska Institutet in Stockholm said in a statement Monday.

    For subscribers


  • Foto: Anushree Fadnavis/Reuters/Ritzau Scanpix

    Country Manager: Indians will have to wait for Wegovy until 2026

    Up to 40% of the female population aged 30-49 in India is overweight.

    For subscribers


  • Foto: Tom Little

    Novo Nordisk files lawsuit against US authorities ahead of price negotiation

    The litigation is the latest in a long line of industry lawsuits related to price negotiations.

    For subscribers


  • Johnson & Johnson shows positive results in lung cancer study

    The Genmab partner’s study has tested antibody treatment Rybrevant and drug candidate Lazertinib in comparison to AstraZenaca’s cancer drug, Tagrisso.

    For subscribers


  • Novo Holdings is upping the ante at US biotech company Avalyn Pharma. | Foto: Novo Holdings / Pr

    Novo Holdings makes another investment in US biotech company

    The money will be used to bring the company’s two drug candidates into phase II as treatments for various lung diseases.

    For subscribers


  • Kallyopes, with which Novo Nordisk formed a partnership in 2018, has initiated a phase II trial of a tablet to treat both obesity and type 2 diabetes. | Foto: Patrick Sison/AP/Ritzau Scanpix

    Kallyope enters Phase II with obesity and diabetes tablet

    US biotech company Kallyope’s anti-obesity and diabetes tablet could be a serious competitor to the current glp-1 analogs, according to the company’s executives.

    For subscribers


  • Foto: Hendrik Schmidt/AP/Ritzau Scanpix

    Investor alliance urges pharmaceutical companies to improve environmental impact

    A number of pharmaceutical companies have been identified as companies that can help reverse the loss of nature and biodiversity.

    For subscribers


  • Scott Thomas Smith, CFO of Ascendis Pharma. | Foto: Ascendis Pharma / Pr

    Ascendis CFO sells shares worth DKK millions

    The deal happens just over a week after Ascendis began the rollout of its weekly growth hormone, Skytrofa, in Europe.

    For subscribers


Latest news

  • Novo Nordisk suffers Wegovy defeat to Viatris in patent court –
  • Pharmaceutical industry to grow 4% annually towards 2030 –
  • Zealand Pharma CEO: "We've never been stronger" –
  • Eli Lilly's head of diabetes and obesity retires –
  • DNB expects ALK's tablet sales to recover in 2024 –
  • Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees –
  • Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom –
  • Novo Nordisk's semaglutide to be studied for positive effect on alcoholics –
  • Olympus appoints new chief medical officer –
  • Low share price may knock Galecto off the stock exchange –
See all

Jobs

  • Senior CMC Specialist, Upstream Processing, Genmab

  • Senior Legal Councel

  • Clinical Trial Manager

  • Scientist - Bioanalysis, Biologics

  • Audit & Supplier Manager

  • VP of Software Development, Perfusion Tech

  • Qualified Person to AJ Vaccines

  • Global Medical Manager

  • Director, Head of Antibody Technology

  • Project Director, HR & ESG

  • Chemist for Incoming Materials in QC department

  • Senior QA Specialists (GMP or GCP)

  • Clinical Supply Manager

  • QA/RA Manager

  • Discovery Project Leader, Principal Scientist

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

  • About MedWatch

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Banner Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved